Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03866213 · ClinicalTrials.gov registry record
Validation of a Jaundice Diagnostic and Monitoring Device for Low-Resource Settings
A clinical trial of Hyperbilirubinemia, Neonatal and Jaundice, Neonatal, sponsored by William Marsh Rice University.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 3
- Study locations
NCT03866213: Recruiting study of Hyperbilirubinemia, Neonatal and Jaundice, Neonatal, sponsored by William Marsh Rice University.
NCT03866213 is a study of Hyperbilirubinemia, Neonatal and Jaundice, Neonatal that is actively recruiting participants, run by William Marsh Rice University. The registered enrollment target is 1,000 participants. The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03866213, a study of Hyperbilirubinemia, Neonatal and Jaundice, Neonatal, is actively recruiting participants, sponsored by William Marsh Rice University.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 3
- Study locations
Study Summary
A team of researchers at Rice University in partnership with clinicians at Queen Elizabeth Central Hospital created BiliSpec, a low-cost battery-powered reader designed to immediately quantify serum bilirubin levels from a small drop of whole blood applied to a lateral flow strip. The simple and affordable BiliSpec system offers a faster and more cost-effective means to detect neonatal jaundice in under-resourced clinics and determine when phototherapy is needed. The goal of this study is to validate the accuracy of the BiliSpec device in measuring bilirubin levels in neonates relative to the laboratory spectrophotometric bilirubinometer and transcutaneous bilirubinometer measurements.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST BiliSpec
Study Locations (3)
Other
- Queen Elizabeth Central Hospital - Blantyre
- Kamuzu Central Hospital - Lilongwe
Texas
- Rice University - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2024-08-31 |
What NCT03866213 shows while recruiting
NCT03866213 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 2 conditions, with Hyperbilirubinemia, Neonatal appearing as the primary indexed condition, and to 1 intervention - of which BiliSpec is the first listed.
NCT03866213 reports a single indexed study location in Other, Texas.
Frequently Asked Questions
What is clinical trial NCT03866213 about?
NCT03866213 is a clinical study titled "Validation of a Jaundice Diagnostic and Monitoring Device for Low-Resource Settings". A team of researchers at Rice University in partnership with clinicians at Queen Elizabeth Central Hospital created BiliSpec, a low-cost battery-powered reader designed to immediately quantify serum bilirubin levels from a small drop of whole blood applied to a lateral flow strip. The simple and aff...
What is the current status of trial NCT03866213?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2019-08-01. Estimated completion is 2024-08-31.
What conditions does trial NCT03866213 study?
This clinical trial studies the following conditions: Hyperbilirubinemia, Neonatal, Jaundice, Neonatal.
What interventions are being tested in trial NCT03866213?
The interventions under investigation include: BiliSpec (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03866213?
This trial is sponsored by William Marsh Rice University, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03866213 being conducted?
This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI